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SUMMARY
Background and objectives. To test if there are different outcomes in basal cell carcinoma 
for lesion size, histopathology, localization, and recurrence rates. 
Materials and methods. A total of 395 patients with BCC localized in the neck, nose and 
ear regions who were surgically treated in Latvian Oncology Centre between 2006-2011 were 
analyzed retrospectively. The data were analyzed using modifi ed classifi cation based on Clarks 
et al. (2014) and McKenzie et al. (2016). 
Results. Three hundred and ninety-fi ve cases of BCC that were surgically treated in head and neck 
region were reviewed. Results were tabulated in four categories: anatomical region, histopathology, 
lesion size, and recurrence rates. Classifi cation by anatomical region: 228 cases in the nose region, 
82 cases in the neck region, 82 cases in the ear region. Classifi cation by histopathology: 259 cases 
presented as low risk BCC [nodular, pigmented, adenoid, keratotic and cystic], 21 cases presented 
as superfi cial, 94 cases presented as mixed, and 21 cases presented as high-risk BCC (metatypical, 
morphea form). Mann-Whitney U test was used to compare recurrent BCC cases to non-recurrent 
cases. Signifi cantly higher recurrence rates were observed if BCC at the time of the excision was ≥ 
10mm (p<0.001). Signifi cance was also noted in cases where histopathology was mixed BCC and 
in cases where mixed BCC was localized to the nose region (p<0.001). 
Conclusion. More attention should be brought to assessing classifi cation and clinical treatment 
synergy. Higher recurrence rates are observed when lesions occur in high risk anatomical region 
(H zone), when lesion size reaches or exceeds 20 mm in diameter, and when lesion is subtyped 
as mixed BCC. It is crucial to evaluate risk factors such as BCC subtype and localization, as 
these are associated with a higher rate of recurrence when present in a single lesion. These risk 
factors, together with pre-treatment lesion evaluation will enable formulation of better treatment 
plan and prognostic aspects in each case.
Key words: basal cell carcinoma, recurrence, head and neck oncology, non-melanoma 
skin cancer.
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INTRODUCTION
Basal cell carcinoma (BCC) is the most frequent 
malignant skin tumor and rates of incidence are 
increasing (1-5). It originates from interfollicular 
epidermal stem cells that simulate keratinocyte char-
acteristics (6-12). The main risk factor is believed to 
be the UV radiation-induced mutations in the PTCH1 
gene which causes the upregulation of hedgehog 
(HH) signaling pathway, but other gene pathways 
have been reported to have a signifi cant role in BCC 
development (6-10). BCC is characterized as a locally 
invasive, slow-growing carcinoma, with infrequent 
rate of metastasis (0.0028-0.5%) (11). Though BCC 
may present as benign, it is well described for its in-
vasiveness involving local anatomical structures (12). 
BCC is commonly classifi ed by three main pa-
rameters: anatomical location, histopathology, and le-
sion size. Dandurand et al. classifi ed BCC according 
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to three anatomical locations based on tumor recur-
rence risk (13). Body and limbs are separated as being 
a part of the low-risk region; forehead, cheek, chin, 
scalp, and neck are regarded as medium-risk regions; 
nose, perioral, and periocular areas are considered 
as a high-risk region. Clark et al. classifi ed BCC by 
anatomical location, histopathology, lesion size, and 
recurrence parameters into low- and high-risk groups 
(14) (Table 1). 
Clark et al. and McKenzie et al. both suggest 
classifying superfi cial BCC as low-risk histopathol-
ogy (14, 15). 
It is not clear how to clinically 
distinguish between “high risk” 
BCC and BCC with relatively 
benign growth (9, 16-18). In ad-
dition, there are opposing views 
on the biological nature, clinical 
course, and the recurrence rates 
of superficial and mixed BCC, 
encouraging researchers to seek 
evidence-based classification 
whether superfi cial BCC belongs 
to ‘low risk” or a “high risk” his-
topathological groups (16-18). 
The aim of this retrospective 
study was to analyze data of surgi-
cally treated patients in Riga East Clinical University 
Hospital, Latvian Oncology Centre (LOC), Depart-
ment of Head and Neck BCC between 2006 to 2011. 
METHODS
Selection of patients 
Patients' data were included in the present study if 
they complied with the following criteria: the tumor was 
histologically proven as BCC; localization of BCC was 
either in nose, neck or ear region (since these localizations 
represent high and low risk anatomi-
cal regions) (13); the tumor was ex-
cised between year 2006 to 2011 (in-
clusive); there was histopathological 
information about size, histological 
subtype and TNM classifi cation (T-
tumor size, N-lymph node metastasis, 
M-distant metastasis). 
Patients' data without follow-
up control were excluded. 
Surgical methodology
Standard conventional surgical 
protocol was used for excision of 
the BCC (19). 
Fig 1. A – case classifi ed as Group IV or mixed BCC histology subtype, larger than 20 mm and located in the nose region. 
B – the patient was treated with WE method and margins were stated as clean. C – after 4 months no recurrence was detected.
A
Fig 2. A – a case classifi ed as Group II or low-risk BCC histology subtype, from 
10 to 20 mm in size and located in the nose region. B – the patient was treated 




Table 1. BCC classifi cation based on size, location, histopathology, and recurrence
Parameters Low risk High risk
Location/size L<20 mm L≥20 mm
M<10 mm M≥10 mm
H<6 mm H≥6 mm
Histological subtype Nodular, superfi cial Demonstrating an aggressive growth 
pattern – morphea form, fi brosing, 
perineural, metatypical, sclerosing, 
mixed infi ltrative or micronodular 
features
Primary vs. recurrent Primary lesion Recurrent lesion
Low-risk area (L) – trunk and extremities. Medium-risk area (M) – cheeks, forehead, 
neck, jawline, scalp, peri-tibial surface. High-risk area (H) – mask areas of the face 
(central face, eyelids, eyebrows, periorbital, nose, lips [cutaneous and vermillion], 
chin, mandible, pre-auricular and post-auricular, temple, and ear, genitalia, hands, 
feet, nail units, ankles, nipples/areola. Table according to Clark et al. (14).
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Based on clinical guidelines, surgeon's experi-
ence, and tumor manifestation, standard excision 
method (SE, 3 mm indention in the healthy soft tissue 
surrounding the tumorous growth) or wide excision 
method (WE, 5 mm indention in the healthy soft tis-
sue surrounding the tumorous growth) was used. The 
intraoperative frozen section was used for all cases. 
If necessary, a free fl ap or rotational fl ap was used to 
close the wound to achieve a better aesthetic result. 
Mohs surgical protocol (microscopically controlled 
surgery) was not used in this study (Fig. 1, 2) (19). 
Classifi cation
Modifi ed classifi cation of Clarks et al. (2014) 
and McKenzie et al. (2016) was used for analysis in 
this study (14, 15). 
BCC was divided into 4 main groups: anatomical 
location, histopathology, lesion size, or recurrence. 
Anatomical location was classifi ed as follows: neck, 
nose, or ear region. Histopathology was divided into 
4 subgroups: group I nodular, pigmented, adenoid, 
keratotic, or cystic BCC; group II consisted of su-
perfi cial BCC; group III of mixed BCC and group 
IV consisted of morphea form, or metatypical BCC. 
Based on Clarks et al. (2014) and McKenzie et al. 
(2016) classifi cation, group I may otherwise be ap-
proached as low risk group, whereas group IV is a 
high-risk group. Lesions were also categorized into 
three subgroups by the following intervals of lesion 
diameter: <10 mm, 10-20 mm, >20 mm (Table 2). 
Each subgroup was further compared according 
to the recurrence or non-recurrence of the lesion. 
Data description
Number labels were assigned to enable anlaysis 
of data using IBM SPSS Software. To assess tumor 
characteristics as numbered data (Table 2), each his-
tological subtype, size and recurrence was labelled 
accordingly. Histological subtype: low risk (label: 
1), superfi cial (label: 2), mixed (label: 3), high risk 
(label: 4). Size: <10 mm (label: 1), 10-20 mm (label: 
2), >20 mm (label: 3). Recurrence: recurrent (label: 
1), non-recurrent (label: 2). 
Statistical Analysis
Data were analyzed in IBM SPSS Software. The 
Kolmogorov–Smirnov test was used to establish the 
normality of the data. If the data were ≥0.05, para-
metric approach was used, however if the data were 
p<0.05, non-parametric approach was indicated and 
Table 2. Distribution of BCC categories.
Histology group Neck Nose Ear
I II III IV I II III IV I II III IV IV
Cases (n) 56 4 21 4 155 10 53 10 48 7 20 7
Recurrence count  (n) 0 1 2 0 1 3 5 2 0 2 3 1
Total of cases (n) 85 228 82
Total of all recurrences (n) 3 11 6
Recurrence rates (%) 3.53 4.82 7.32
Histology is divided by histological subgroups: group I – nodular, pigmented, adenoid, keratotic and cystic; group II – su-
perfi cial; group III – mixed, group IV – morphea form, metatypical. Anatomical distribution is divided into three anatomical 
locations: neck, nose, and ear. Recurrence rates were calculated as total recurrences divided by total cases. n – number of cases.
Table 3. Distribution of recurrent and non-recurrent BCC by tumor size, histology group, and anatomical location.
Region Recurrence Non-recurrence P value*
n Med (25%; 75%) KS sig. level n Med (25%; 75%) KS sig. level
Histology
Ear 6 3.00 (2.00; 3.25) 0.272 76 1.00 (1.00; 3.00) <0.001 0.009
Neck 3 3.00 (2.00; 3.00) 0.766 82 1.00 (1.00; 3.00) <0.001 0.042
Nose 11 3.00 (2.00; 3.00) 0.178 217 1.00 (1.00; 3.00) <0.001 <0.001
Total 20 3.00 (2.00; 3.00) 0.082 375 1.00 (1.00; 3.00) <0.001 <0.001
Size
Ear 6 2.00 (2.00; 3.00) 0.748 76 1.00 (1.00; 2.00) <0.001 0.041
Neck 3 3.00 (2.00; 3.00) 0.766 82 2.00 (1.00; 2.00) <0.001 0.057
Nose 11 3.00 (2.00; 3.00) 0.469 217 2.00 (1.00; 2.00) <0.001 0.005
Total 20 2.50 (2.00; 3.00) 0.035 375 2.00 (1.00; 2.00) <0.001 <0.001
Med – median, 25% – fi rst quartile, 75% – third quartile; n – count; P value – signifi cance level 0.05. KS sig. level – Kol-
mogorov Smirnov test signifi cance level 0.05. Size: <10 mm (labelled: 1), 10-20 mm (labelled: 2), >20 mm (labelled: 3).
Histology: low risk – group I (labelled: 1), superfi cial – group II (labelled: 2), mixed – group III (labelled: 3), high-risk – 
group IV (label: 4). As all of the data were non-parametric (KS sig.<0.001), the  Mann-Whitney U test was used for assessing 
signifi cance of difference in recurrence and non-recurrence by histology group or tumor size.
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Mann-Whitney U test was used. Signifi cance was 
accepted at p<0.05 and all values are expressed as 
median (25% – fi rst quartile; 75% – third quartile) for 
the data. Results from Kolmogorov-Smirnov test and 
Mann-Whitney U test were summarized in Table 3. 
RESULTS
From 2006 to 2011, 905 operated BCC cases in 
LOC, Department of Oral and Maxillofacial Surgery. 
The average age was 62.2 (min. 21 y., max. 95 y.) 
and sex of the patients were distributed as follows: 
321 males, 584 females. Anatomical locations of 
BCC lesions were distributed as follows: 113 cases 
in the frontal region, 93 cases in the orbital region, 
186 cases in the cheek region, 283 cases in the nose 
region, 132 cases in the ear region and 98 cases in 
the neck region. From 905 cases, 395 cases were 
selected based on exclusion criteria as follows: 392 
cases were excluded due to the anatomical location, 
86 cases due to the lack of information on specifi c 
subtype of BCC, 18 cases due to the lack of informa-
tion on lesion dimensions, 3 cases due to the lack of 
information on TNM classifi cation. Three hundred 
and ninety-fi ve cases (99 males, 296 females) were 
selected based on selection criteria. The average age 
was 62. 5 (min. 21 y., max. 95 y.). 
Cases were divided as shown in Table 2. There 
were 5. 1% (n=20) recurrent cases out of a total of 
395 BCC cases. Two hundred and twenty-eight cases 
(57.7%) were located in the nose region. The neck 
region was affected in 21.5% (n=85) cases and ear 
region in 20.8% (n=82) cases. Low risk (group I) BCC 
was found in 65.6% (n=259) cases, superfi cial (group 
II) BCC was identifi ed in 5.3% (n=21) cases, mixed 
(group III) BCC was identifi ed in 23.8% (n=94) 
cases and high risk (group IV) BCC was diagnosed 
in 5.3% (n=21) cases. The fl owchart shown in Fig-
ure 3 illustrates the case distribution between BCC 
characteristics [total number of cases → divided per 
anatomical region → histopathological classifica-
tions by group in each anatomical region → lesion 
classification by size]. 
The distribution of recurrent cases according to 
location: nose region 55% (n=11); ear region 30% 
(n=6); neck region 15% (n=3). Group III (mixed 
BCC) reoccurred in 50% (n=10) of all cases whereas 
group II (superficial BCC) in 30% (n=6), group IV 
(morphea form, metatypical BCC) in 15% (n=3) and 
group I (nodular, pigmented, adenoid, keratotic and 
cystic BCC) in 5% cases (n=1). 
In Table 3 recurrent cases were compared with 
non-recurrent cases. The Kolmogorov Smirnov test 
was used to assess the data normality. As all of the 
data were non-parametrical (<0.001), the Mann-
Whitney U test was used to determine the significance 
of the difference between groups according to histo-
logical and size parameters. The mixed BCC subtype 
dominated in terms of recurrence (50th quartile mixed 
BCC/p<0.001). The statistical median for the size 
characteristic was larger than 20 mm in the neck and 
nose region and 10-20 mm in the ear region (Table 3). 
In non-recurrent cases, all of the anatomical 
regions were observed with the low-risk histopatho-
logical subtype. In the neck and nose region, the 
statistical median size was 10-20 mm, but in the ear 
region, it was less than 10 mm in diameter (Table 3). 
Significantly higher recurrence rates were ob-
served if BCC at the time of the excision was 10-20 
mm or larger (p<0.001). Significance was also noted 
for mixed BCC histopathology and for cases where 
mixed BCC was localized in the nose region (Table 
3, p<0.001). 
The superficial subtype was the second most 
recurrent subtype in this study. In the Mann-Whitney 
U test, the superficial subtype appeared in every ana-
tomical region in 25th quartile. No significant differ-
ence was found between recurrent and non-recurrent 
cases when excisions were carried out on other BCC 
subtypes (Table 3). 
DISCUSSION
It is essential to assess the quality of life of the 
patient in the relationship to oncological radicalism 
with functional and aesthetic surgery approach (20). 
Although recurrence rates of treated BCC have de-
creased, some studies still report rates reaching up to 
15% (6, 8). Since BCC is most commonly located in 
the facial region, aesthetical and functional expecta-
tions may influence the surgical approach. Current 
classifications that are determined by lesion charac-
teristics such as location, histopathology, and lesion 
size, must be taken into account so that the primary 
treatment goal of reducing recurrence rates might be 
achieved (9, 19, 21, 22). 
Our study has significantly lower male to female 
ratio than other studies in the literature. We cannot 
directly address the cause of this bias in our study, 
but variation in sex ratios are not uncommon. In 
some reports, the higher incidence of BCC in men 
versus women (1. 5:1 (23), 1. 4:1 (24), 1. 3:1 (25), 1. 
1:1 (26)) is explained by the higher use of protective 
sunscreens by women or by the higher frequency of 
outdoor physical work (higher sun exposure) for men. 
In other reports, the incidence of BCC is either more 
equally distributed between men and women (1. 1:1 
(26), 1. 1:1 (27)) or the incidence is higher in wom-
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en (1:1.1 (9), 1:1.3 (28), 
1.1:1 (29), 1:1.6 (30), 1:1.4 
(31)). Before applying the 
exclusion criteria, the male 
to female ratio was 1:1.81; 
after the exclusion criteria 
were applied, the male to 
female ratio was 1:2.99. 
The largest portion of ex-
cluded patients (80% of 
total excluded) was due to 
the anatomical location of 
the BCC. Ghanadan et al. 
(2014) found that males 
had a higher frequency 
of BCC on the scalp than 
females (32). Scrivener 
et al. (2002) attributes 
such male to female ratio 
with increasing female 
predominance to age- and 
sex-dependent mortality; 
pathologies such as car-
diovascular and internal 
oncology occur earlier in 
men. 
Average age was not 
different after application 
of exclusion criteria (62.2 
yrs. before, 62.5 yr.) and 
according to Eurostat, the 
cardiovascular and oncol-
ogy related mortality in 
men was almost 3-fold 
higher than for women for 
the population 65 yrs. old 
and younger (33). A study 
evaluating almost 30 years 
of data gathered in Nether-
lands report BCC incidence 
in woman increasing with 
a faster rate than in man 
and even higher increase 
in incidence for younger 
woman (<50 yrs.) (2). Sev-
eral studies have also re-
ported clinically observed 
BCC significantly higher 
in men aged between 70-79 
yrs. , whereas other stud-
ies report an increase of 
incidence in women aged 
40-49 or aged 60-79 (23, 
34). These studies report 
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a tendency of clinical diagnosis made in men later 
in their age compared to women. One could surmise 
that either men are predisposed to BCC at an older 
age than woman or woman are more attentive to 
the anatomical changes in the head and neck region 
(or both). The current analysis does not include sex 
as a variable as we have too small a sample size to 
sufficiently address this along with the variables 
examined. We can offer some speculation based on 
the reports in other studies cited here that if the male 
to female ratio would been closer to 1:1, we would 
expect to have observed more large lesion sizes and 
higher recurrence rates. It is possible that our study 
population has resulted in an underestimation of some 
associations of variables to recurrence outcomes 
because of the low male: female ratio. 
A significant difference was observed between 
recurrent and non-recurrent cases when comparing 
differences in lesion size (p<0.005, Table 3). This 
may suggest that most of the recurrent cases were 
diagnosed when the tumor was larger than 10 mm 
([10-20;>20] mm, p<0. 001, Table 3) where as non-
recurrent cases did not reach size above 20mm. Sig-
nificantly higher recurrence rates in cases of a tumor 
larger than 10 mm is in disagreement with Demirseren 
et al. (2014) reporting no connection between size 
and sex with recurrence rates (35). Some studies have 
proposed excision guidelines for BCC with larger 
healthy tissue indentations if the lesion is at least 20 
mm in diameter (19). Most of the recurrent cases in 
the present study were observed in the high risk (H) 
zone. In fact, significantly higher recurrence was 
observed when mixed subtype was localized in the 
nose region (50th quartile mixed, localization: nose, 
p<0.001, Table 3). It is more likely that characteristics 
such as size and histopathology, in addition to the 
early recognition and treatment of zones of particular 
aesthetic concern, may have influenced the associa-
tions in this study, as they have in others (36). 
The mixed histological subtype, by virtue of its 
name, consists of variety of BCC cell growth char-
acteristics. Ghanadan et al. (2014) analyzed mixed 
BCC in terms of a combination of its components and 
classified each combination in terms of their occur-
rence rates (16). Their study shows the complexity of 
mixed BCC subtype and may explain the differences 
in results between studies due to skin type, genetics, 
and environment (21). Although such classifica-
tions may improve the understanding of mixed BCC 
subtype, it may be too clinically complex to assist 
in differential diagnosis, and it may not change the 
prediction of patients’ post-surgical outcome. 
In this study the histopathological difference was 
found to be significant between non-recurrent and 
recurrent cases. Low risk BCC was far more prevalent 
in non-recurrent cases (50th quartile low risk [25th 
low risk; 75th mixed], p<0.001, Table 3). However 
mixed BCC appeared significant in recurrent cases 
(50th quartile mixed [25th superficial, 75th mixed], 
p<0.001, Table 3). As this study did not include an 
evaluation of the infiltrative subtype of BCC, or 
the proportion of this subtype in the mixed subtype 
group, the only group that clearly resembles high 
risk histopathological characteristics is group IV or 
high-risk group (morpheaform and meatypical) based 
on Clarks et al. (2014) classification (14, 37). In this 
study, high risk BCC comprised only 15% of recurrent 
cases while mixed BCC comprised 50% of recurrence 
cases. We were unable to evaluate histopathological 
components for the mixed BCC subtype because the 
patient dataset did not include these components. This 
is a weak point in the present study as we cannot say 
for certain that high risk components in recurrent 
mixed BCC cases were present (10, 16, 24, 25). Two 
risk factors such as mixed subtype (if infiltrative 
or micronodular component is present) and H zone 
localization may explain the significant findings of 
recurrent cases in present study (38-41). 
The rates of recurrence in this study were 5. 06% 
(20 cases of 395) which is in accordance with reported 
recurrence rates of 3.2% to 8.0% (19). The mixed 
histological subtype accounted for 50% of recurrent 
cases (10 cases of 395) which is also in agreement 
with many studies (12, 16, 25). 
C lark et al. (2014) and McKenzie et al. (2016) 
suggest classifying superficial BCC as low risk sub-
type in histopathological terms (14, 15). Our study 
showed that in every anatomical group, superficial 
BCC reaches the 25th quartile of the median within 
recurrent cases and comprised 6 of the 20 recurrent 
cases. Why is superficial BCC (low risk) the second 
rank in recurrent cases? One explanation may be 
that the surgical excision procedure did not include 
the MOHS approach which is the accepted golden 
standard for the surgical treatment in BCC cases, 
thus excision margins could have been overlooked 
in cases of superficial subtype. As recurrence rates 
in this study do not differ much (or at all) from other 
studies reporting these rates in MOHS surgery, this 
may not contribute significantly to this observation. A 
randomized controlled trial and prospective random-
ized control trial with 5-year follow-up showed simi-
lar results achieving no significant difference between 
standard excision method and MOHS surgery (42, 
43). High recurrence rates in superficial BCC have 
been reported previously (40). While this study found 
significant results in terms of cell growth patterns, 
anatomical location and lesion size, contradictory 
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results are still being reported in disagreement with 
current classifications (8, 18). 
The analysis in this study was limited by sample 
size; this precluded the inclusion of sex as a variable 
in the analysis. The clinical records in our study did 
not include a description of the components of the 
mixed BCC subtype, which precluded an analysis of 
recurrence with the components (for example, with 
mixed BCC infiltrative or micronodular). As we eval-
uated more than 2 characteristics of BCC, one may 
suggest a multivariate analysis (per ex. MANOVA) 
that may help to identify new risk factors. We could 
not reasonable apply such an analysis given that the 
recommended sample size is not lower than n=50 for 
the results to be reliable (44). 
CONCLUSIONS
Size, anatomical location and histopathological 
subtype were significant characteristics in recurrent 
cases in comparison with non-recurrent cases. Le-
sions that were 10 mm or larger in diameter, lesions 
found in nose region and lesions with mixed subtype 
characteristics were significant to recurrent cases. 
More attention should be focused on patients with 
such risk factors and pre-treatment lesion evaluation 
per classification (including a characterization of 
mixed BCC) should be done. 
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